GlassScriptPhysician profile
Sameh Askandar
NPI 1154736239
$3,317.47
in general payments reported to CMS, 2019-2025
25 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.73 · 2021: $28.80 · 2022: $470 · 2023: $324 · 2024: $1,321 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $797.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Eli Lilly and Company | $470.00 | 2022 | |
| Lilly USA, LLC | $447.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $277.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $156.62 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $136.00 | 2024-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $107.45 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $107.43 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $100.62 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $99.23 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $90.33 | 2024-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.08 | 2024-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $69.07 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $68.24 | 2025 | |
| Dynavax Technologies Corporation | $46.74 | 2024 | Heplisav-B |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $44.07 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $40.99 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $31.32 | 2025 | Inspire |
| Sobi, INC | $28.80 | 2021 | |
| Abbott Laboratories | $24.40 | 2025 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $22.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.88 | 2024 | Voquezna |
| Convatec INC. | $21.79 | 2025 | |
| Abbvie INC. | $20.25 | 2024 | |
| Genentech USA, INC. | $18.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Askandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.